TABLE III
REPORTED DISEASES BY MONTH <sup>1 2 3</sup> - TEXAS, 2020 <sup>4</sup>

DISEASE	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	ОСТ	NOV	DEC	TOTAL
AMEBIASIS	8	8	-	-	-	-	-	-	-	6	-	-	44
AMEBIC MENINGITIS, OTHER	0	0	-	0	0	0	0	0	0	0	0	-	-
AMEBIC MENINGOENCEPHALITIS, PRIMARY	0	0	0	0	0	0	0	0	-	0	0	0	-
ANAPLASMOSIS	0	0	0	0	0	0	-	0	0	0	0	0	-
ANCYLOSTOMIASIS (HOOKWORM)	0	-	0	0	0	0	0	0	0	0	0	0	-
ANTHRAX	0	0	0	0	0	0	0	0	0	0	-	0	-
ASCARIASIS	0	-	-	0	-	-	0	0	-	0	0	•	7
BABESIOSIS	0	0	0	0	0	0	-	-	0	-	0	0	-
BOTULISM, INFANT	0	-	-	0	-	0	-	0	-	-	-	•	10
BOTULISM, WOUND	0	0	-	0	0	0	0	-	-	0	-	5	9
BRUCELLOSIS	0	-	5	-	-	-	-	-	-	-	0	-	17
CALIFORNIA SEROGROUP VIRUSES <sup>5</sup>	0	0	0	0	0	0	0	0	-	0	0	0	-
CAMPYLOBACTERIOSIS	265	217	206	194	305	358	269	233	191	233	299	179	2,949
CARBAPENEM-RESISTANT ENTEROBACTERIACEAE	71	56	55	58	75	52	59	81	69	65	49	61	751
CHAGAS DISEASE	-	-	5	0	-	-	-	-	-	0	-	-	19
CHICKENPOX (VARICELLA)	104	79	39	9	10	10	8	13	20	26	15	15	348
CHIKUNGUNYA	-	-	0	0	0	0	0	-	0	0	0	0	-
CRYPTOSPORIDIOSIS	53	38	36	34	30	29	30	22	26	33	14	20	365
CYCLOSPORIASIS	0	5	-	5	6	120	272	157	13	0	-	-	581
CYSTICERCOSIS	0	-	-	-	-	0	0	-	0	0	0	0	6
DENGUE	7	-	0	0	0	0	0	0	7	29	17	-	62
ECHINOCOCCOSIS	0	0	0	0	0	0	0	0	-	-	0	0	-
EHRLICHIOSIS	0	0	0	-	0	0	-	-	0	-	-	-	8
ESCHERICHIA COLI, SHIGA TOXIN-PRODUCING (STEC)	70	46	48	25	46	37	37	35	53	55	41	20	513
HAEMOPHILUS INFLUENZAE, INVASIVE <sup>6</sup>	65	41	30	16	8	7	6		-	9	10	6	206
HEMOLYTIC UREMIC SYNDROME	0	0	0	0	-	-	0	0	-	-	0	0	5
HEPATITIS A, ACUTE	15	18	23	6	14	12	28	22	10	12	25	38	223
HEPATITIS B, ACUTE	6	-	-	5	-	-	-	-	6	-	5	7	50
HEPATITIS C, ACUTE	5	6	-	-	-	-	-	-	5	-	0	5	38
HEPATITIS E, ACUTE	0	-	-	-	-	0	0	0	0	-	0	-	9
INFLUENZA-ASSOCIATED PEDIATRIC MORTALITY <sup>78</sup>	-	-	-	0	0	0	0	0	0	0	0	0	10
LEGIONELLOSIS	36	24	31	27	24	18	22	20	32	33	24	26	317
LEISHMANIASIS	0	0	-	0	0	0	0	0	0	0	0	0	-
LISTERIOSIS	-	-	7	-	0	-	-	-	-	-	6	-	33
LYME DISEASE	0	0	0	0	0	-	5	-	-	0	0	0	11
MALARIA	16	5	-	-	-	-	0	-	-	-	6	-	47
MENINGOCOCCAL INFECTION <sup>9</sup>	-	-	-	-	-	0	0	-	0	-	0	0	17
MULTIDRUG-RESISTANT ACINETOBACTER (MDR-A)	102	87	92	55	80	68	132	122	98	83	76	61	1,056
MUMPS	5	-	7	0	0	-	0	-	0	-	-	0	22
PERTUSSIS	102	88	45	45	22	6	-	7		6	7	9	343
Q FEVER	-	0	0	-	-	-	0	0	0	0	0	0	5
RICKETTSIOSIS, UNSPECIFIED <sup>10</sup>	0	0	0	-	0	0	-	0	-	0	0	-	5
RUBELLA	-	0	0	0	0	0	0	0	0	0	0	0	-
SALMONELLOSIS	242	121	140	167	275	255	274	362	443	409	197	151	3,036
SHIGELLOSIS	351	368	230	65	43	53	45	46	37	55	54	38	1,385
SPOTTED FEVER RICKETTSIOSIS	0	-	-	-	0	-	-	0	0	-	-	0	12
ST. LOUIS ENCEPHALITIS VIRUS <sup>11</sup>	0	0	0	0	0	0	0	0	-	-	0	0	-
STREPTOCOCCUS PNEUMONIAE, INVASIVE	231	184	113	35	28	31	38	21	31	35	41	52	840
STREPTOCOCCUS, GROUP A, INVASIVE	114	81	62	44	34	28	34	25	19	30	35	39	545
STREPTOCOCCUS, GROUP B, INVASIVE	154	128	107	129	117	114	126	122	110	110	108	77	1,402
TAENIASIS	0	0	0	0	0	-	0	0	0	0	-	0	-
TETANUS	0	0	0	0	0	0	0	0	0	-	0	0	-
TYPHOID FEVER	-	-	0	0	0	0	0	-	-	0	0	-	10
TYPHUS, FLEA-BORNE (ENDEMIC, MURINE)	34	30	24	48	105	96	42	40	26	28	33	20	526
VIBRIO PARAHAEMOLYTICUS	0	0	-	0	0	-	-	5	-	-	0	0	12
VIBRIO VULNIFICUS	0	0	0	-	-	6	-	-	-	-	-	0	21
VIBRIO, OTHER/UNSPECIFIED	10	6	6	5	6	11	5	6	6	-	-	-	67
VISA <sup>12</sup>	-	0	0	0	0	0	0	0	-	0	-	0	
WEST NILE FEVER	0	0	0	0	-	-	-	7	5	-	-	0	21
WEST NILE NEUROINVASIVE DISEASE	0	0	0	0	0	0	17	51	22	7	-		101
YERSINIOSIS	13	15	9	12	12	8	5	15	6	8	9	5	117
Note: Por Emorging and Acute Infactious Disease Unit De													

Note: Per Emerging and Acute Infectious Disease Unit Data Suppression policy, beginning with data published after September 2021, subgroup case counts of 1-4 and fatalities counts of 1-9 are not provided (-). Additional counts (--) are suppressed to prevent back-calculation of suppressed small counts.

1 Event month for each condition and/or case may be month of onset, or month of diagnosis, report, or other event that approximates onset.

<sup>2</sup> Diseases listed reflect those that were notifiable in Texas based on Texas Administrative Code and where cases were reported in the current

reporting year. Counts are by calendar month. Case counts are presumed to be underestimates of true disease incidence due to incomplete reporting.

Data in this table may not match tables in articles in this publication that were written prior to completion of data review for this report, or other previously published materials.

<sup>3</sup> Prion Disease is not included in this table.

<sup>4</sup> Due to the extenuating circumstances arising from the COVID-19 Pandemic, a considerable decline in the reported number of cases was noted across many notifiable conditions by the Texas Department of State Health Services for 2020. Thus, the reported case counts and associated rates may not accurately reflect the incidence of disease in the population.

<sup>5</sup> California serogroup viruses include<del>s</del> California encephalitis, La Crosse, Jamestown Canyon, Keystone, snowshoe hare, and trivittatus viruses.

<sup>6</sup> Effective in 2016, Haemophilus influenzae type b infection, invasive was expanded to all invasive Haemophilus influenzae regardless of type.

<sup>7</sup> Infant botulism cases are for patients under 1 year of age by definition.

<sup>8</sup> Influenza-associated pediatric mortality cases are under 18 years of age by definition.

<sup>9</sup> Includes all cases of invasive Neisseria meningitidis including cases of meningitis, septicemia, and joint infections.

<sup>10</sup> Rickettsiosis, unspecified replaced "dual reporting" in typhus/spotted fever cases in 2015. It was added to the Epi Case Criteria Guide in 2016 and defined as clinically compatible cases with serological evidence of elevated IgG or IgM antibody reactive with spotted fever and typhus group antigens by IFA that cannot be classified as either flea-borne typhus or spotted fever group rickettsioses.

<sup>11</sup> These arbovirus counts include both neuroinvasive and non-neuroinvasive cases.

 $^{12}$  Vancomycin-intermediate resistant *Staphylococcus aureus* (VISA)--*Staphylococcus aureus* with a vancomycin minimum inhibitory concentration (MIC) of 4 µg/mL through 8 µg/mL.